急性冠心症患者於急性期使用ß-拮抗劑對於阻止左心室重塑之臨床經驗

A study of the use of β-blocker in acute stage of acute coronary syndromes in the prevention of left ventricular remodeling

賴小慧(Sow-Fei Lai)

指導教授 ： 詹道明

高雄醫學大學/藥學院/天然藥物研究所碩士班/碩士(2019年)

摘要

研究目的：測定Carvedilol，第三代ß-抗拮劑對急性冠心症病患的心臟保護作用
方法：病患來自屏東寶建醫院心臟內科，研究組之病患在胸痛症狀後六小時內開始給予Carvedilol，在急性期及三個月後，心臟超音波追蹤記錄：左心室舒張末期容積，左心室收縮期末容積及左心室排出分數。
結果：三個月後之追蹤比較，經由Analysis of variance (ANOVA)得知，左心室排出分數(left ventricular ejection fraction，LVEF)研究組高於對照組，P值為0.0435(P＜0.05) 有統計學上之意義，但兩組於左心室舒張期末容積(left ventricular end diastolic volume，LVEDV)方面，沒有統計學意義上之差別。
結論：於急性冠心症早期開始投予Carvedilol有減低心室重塑之效果。

關鍵字

左心室舒張期末容積 ； 左心室排出分數 ； 心室重塑

並列摘要

Objective: The aim of this study was to determine the cardiac protective effects of carvedilol, a third generation beta-adrenergic blocker, in acute stage of acute coronary syndromes.
Methods: Patients from Department of Cardiology, Pao Chien Hospital were recruited for this echocardiographic study. In the study group patients started with carvedilol 6 hours within chest pain attack. Echocardiography, measuring left ventricular end diastolic volume (LVEDV)，left ventricular end systolic volume (LVESV)，left ventricular ejection fraction (LVEF) were performed then and repeated after 3 months.
Results: At 3 months, left ventricular ejection fraction was significantly rise in the carvedilol group (P＝0.0435) (ANOVA). Left ventricular end diastolic volume was not statistically different between the two groups.
Conclusions: Early administration of carvedilol in Acute Coronary Syndromes results in attenuation of left ventricular remodeling.

並列關鍵字

left ventricular ejection fraction ； remodeling ； left ventricular end diastolic volume

參考文獻

1.Yeghiazarians Y, Braunstein JB, Askari A and Stone PH. Unstable angina pectoris. N Engl J Med 2000;342:101-114

2.Hong MK, Mintz GS, Lee CW, Kim YH, Lee SW, Song JM, Han KH, Kang DH, Song JK, Kim JJ, Park SW and Park SJ. Comparison of coronary plaque rupture between stable angina and acute myocardial infarction: A three-vessel intravascular ultrasound study in 235 patients. Circulation 2004;110:928-933

3.Goto S, Tamura N and Ishida H. Ability of anti-glycoprotein IIb/IIIa agents to dissolve platelet thrombi formed on a collagen surface under blood flow conditions. J Am Coll Cardiol 2004;44:316-323

4.Bhatt DL and Topol EJ. Current role of platelet Glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. JAMA 2000;284:1549-1558

5.Bolognese L, Ducci K, Angioli P, Falsini G, Liistro F, Baldassarre S and Burali A. Elevations in Troponin I after percutaneous coronary interventions are associated with abnormal tissue-level perfusion in high-risk patients with non–ST-segment–elevation acute coronary syndromes. Circulation 2004;110:1592-1597